Date: 11th August, 2023

To, The Manager (Listing) BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001

Ref: Scrip Code No. 506260 Sub: Outcome of Board Meeting dated 11th August, 2023.

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the Board of Directors of the Company (the "Board") at its Meeting held today i.e. Friday, 11th August, 2023, inter-alia considered and approved the following agenda Items:

1. The Un-Audited Financial Results along with Limited Review Report thereon for the quarter ended 30th June, 2023.

The Meeting of the Board of Directors commenced at 12.45 PM and concluded at 4.15 PM.

Thanking you,

Yours faithfully, For Anuh Pharma Ltd.

HEMANT KISAN AUTI Digitally signed by HEMANT KISAN AUTI Date: 2023.08.11 16:09:42 +05'30'

Hemant Auti Company Secretary & Compliance Officer

Encl: Un-audited Financial Results along with Limited Review Report

JAYANTILAL THAKKAR & CO. 111 (A), MAHATMA GANDHI ROAD. CHARTERED ACCOUNTANTS FORT, MUMBAI - 400 023

TELEPHONES : 2265 8800 2265 8900 FAX: (91-22) 22658989 E-MAIL : [email protected]

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of Anuh Pharma Limited (the "Company") Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

TO THE BOARD OF DIRECTORS Anuh Pharma Limited

• 1. We have reviewed the accompanying statement of unaudited financial results of Anuh Pharma Limited (the "Company") for the quarter ended 30th June, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
• 1. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
• 4, Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For JAYANTILAL THAKKAR & CO. CHARTERED ACCOUNTANTS (FIRM REG. NO. 104133W) VISHAL D. SHAH PLACE: Mumbai PARTNER

DATE: 11* August, 2023 MEMBERSHIP NO. 123337 UDIN: 23123337BGQBSM4239

ANUH PHARMA LTD.

CIN: L24236MI1960PLCO11586

Regd, Office : 3-A, North Wing, Shivsagar Esfate, Dr. Annie Besant Road, Worll, Mumbai - 400018 1: 491 22 6622 7575; Fax: +91 22 6622 7600; Batl: [email protected]; Website: wiww.anubpharia.con ; UNAUDIT FINANCIAL RESUL OR THE QUARTER ENDED 30th JUNE, 2023

Notes:-

1. The results of the quarter ended 30th June ,2023 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on L1th August, 2023.The statutory auditors of the Company carried out a "Limited Review" of the financial results for quarter ended 30th June ,2023

1. The figures for the quarter ended 31st March, 2023 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year.

2. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with thel requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

3. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anub Pharma Ltd.

Place : Mumbai Joint Managing Director

|

Date : 11th August, 2023 (DIN: 02496729)